Trial Profile
Long-term Study to Observe Safety and Efficacy of TAF in Patients With Chronic Hepatitis B
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2020
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- 23 Jun 2020 Planned End Date changed from 16 Aug 2020 to 16 Sep 2020.
- 23 Jun 2020 Planned primary completion date changed from 15 May 2020 to 15 Aug 2020.
- 10 Mar 2020 Planned End Date changed from 16 Apr 2020 to 16 Aug 2020.